Effects of ACEI on Bone Turnover

Completed

Conditions studied: Bone Turnover Status in Hypertensive Patients

In brief

The investigators hypothesize that older persons (≥45 years) treated with ACEI for HTN control will have: i) improved status of bone turnover (decreased P1NP and CTX), and ii) decreased levels of RANKL and RANKL/OPG, compared to those not treated with ACEI and not using RAS-related medications

Key facts

Study ID

NCT02377440

Run by

The University of Texas Health Science Center, Houston

People needed

32

Starts

2013-10-01

Expected to finish

2015-12-01

Last updated by the study team

2015-12-04

Who can join

Age: 45 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• at least 45 years of age
• a diagnosis of (either new or uncontrolled) HTN who will need a new medication for HTN control
• able to consent (no medial issues impairing judgment for consenting based on clinical providers' judgment).

You may not qualify if…

• younger than 45 years of age
• a diagnosis of metabolic bone disease
• a diagnosis of osteoporosis or use of medication to treat osteoporosis
• a diagnosis of diabetes mellitus, or renal insufficiency, or cancer
• history of allergy to ACEI or ARB, 6) history of use of ACEI or ARB.

Where it is running

• Nahid Rianon, MD — Houston, Texas, United States
• University of Texas Medical School at Houston — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.